Alizarin (Anthraquinonic) strongly inhibits P450 isoform CYP1A1, CYP1A2 and CYP1B1 with IC50 of 6.2 ?M, 10.0 ?M and 2.7 ?M, respectively; weakly inhibits CYP2A6 and CYP2E1, and does not inhibit CYP2C19, CYP3A4 and CYP3A5. *For Research & Development use only. Product is not intended for drug, household, or human consumption.